Amanote Research
Register
Sign In
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Pharmaceuticals
- Switzerland
doi 10.3390/ph3041122
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Pharmaceutical Science
Date
April 15, 2010
Authors
Roberta Ferraldeschi
William G. Newman
Publisher
MDPI AG
Related search
CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply
British Journal of Clinical Pharmacology
Pharmacology
Laboratory Testing of CYP2D6 Alleles in Relation to Tamoxifen Therapy
Genetics in Medicine
Medicine
Genetics
Limited Predictive Value of Achieving Beneficial Plasma (Z)-Endoxifen Threshold Level by CYP2D6 Genotyping in Tamoxifen-Treated Polish Women With Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
CYP2D6 Genotyping in the Daily Routine of a Psychiatric Hospital – Pharmacoeconomic Evaluation
PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology
CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
Clinical Pharmacology and Therapeutics
Pharmacology
CYP2D6 Polymorphisms and Their Influence on Risperidone Treatment
Pharmacogenomics and Personalized Medicine
Molecular Medicine
Pharmacology
Cost-Effectiveness of Cyp2d6 Genotyping in Older Depressed Patients, Starting With Nortriptyline Therapy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated With Tamoxifen
Frontiers in Pharmacology
Pharmacology
Duration of Adjuvant Tamoxifen Treatment
Breast Cancer Research
Cancer Research
Oncology
